You are here: Industry Insights > Lilly

News List

Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progres lilly
March 21, 2017
Abemaciclib, in combination with fulvestrant, was superior to fulvestrant plus placebo in patients with HR+, HER2- advanced breast cancer
Lilly Diabetes Becomes 'Official Diabetes Health Partner of NASCAR®' lilly
March 06, 2017
NASCAR® and Lilly Diabetes announced today that Lilly is expanding its involvement in NASCAR with a multi-year official partnership with the sanctioning body.
New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Comp lilly
March 06, 2017
Eli Lilly and Company announced that patients with moderate-to-severe plaque psoriasis treated with Taltz® (ixekizumab) demonstrated superior efficacy at 24 weeks compared to patients treated with Stelara®* (ustekinumab).
Lilly Announces Changes in Senior Management lilly
March 03, 2017
Fionnuala Walsh retiring, Johna Norton promoted; Bart Peterson leaving to pursue external interests
Lilly Completes Acquisition of CoLucid Pharmaceuticals lilly
March 02, 2017
Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of CoLucid Pharmaceuticals, Inc. (NASD:CLCD).
EC approves once-daily Olumiant tablets for treatment of adults with active RA cphi-online
February 16, 2017
Baricitinib, marketed as Olumiant, is the first JAK inhibitor approved to treat RA in the EU.
European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Se lilly
February 14, 2017
Eli Lilly and Company announced today that the European Commission has granted marketing authorisation for Olumiant® (baricitinib) 4 mg and 2 mg film-coated tablets in Europe for the treatment of moderate-to-severe active rheumatoid arthritis (RA)...
Carolyn R. Bertozzi, Ph.D., Elected to Lilly Board of Directors lilly
February 10, 2017
The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Carolyn R. Bertozzi, Ph.D., as a new member, effective Feb. 10, 2017. As a member of Lilly's board, she will serve on the Science and Technology and Public Policy and Compliance Commi
Eli Lilly to aquire pain biotech CoLucid for $960 million europeanpharmaceuticalreview
January 20, 2017
Eli Lilly and Company will acquire CoLucid Pharmaceuticals for $46.50 per share or approximately $960 million. This all-cash transaction will enhance Lilly’s existing portfolio in pain management for migraine, while adding a potential near-term launch to
Lilly to Acquire CoLucid americanpharmaceuticalreview
January 20, 2017
Eli Lilly and CoLucid Pharmaceuticals have announced an agreement for Lilly to acquire CoLucid for $46.50 per share or approximately $960 million.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page